|
1
|
Wen PY and Kesari S: Malignant gliomas in
adults. New Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ostrom QT, Gittleman H, Truitt G, Boscia
A, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical report:
Primary brain and other central nervous system tumors diagnosed in
the United States in 2011–2015. Neuro Oncol. 20 (Suppl 4):iv1–iv86.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Patel NP, Lyon KA and Huang JH: The effect
of race on the prognosis of the glioblastoma patient: A brief
review. Neurol Res. 41:967–971. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Taphoorn MJ, Sizoo EM and Bottomley A:
Review on quality of life issues in patients with primary brain
tumors. Oncologist. 15:618–626. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pasquinelli AE: MicroRNAs and their
targets: Recognition, regulation and an emerging reciprocal
relationship. Nat Rev Genet. 13:271–282. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li XT, Wang HZ, Wu ZW, Yang TQ, Zhao ZH,
Chen GL, Xie XS, Li B, Wei YX, Huang YL, et al: miR-494-3p
regulates cellular proliferation, invasion, migration, and
apoptosis by PTEN/AKT signaling in human glioblastoma cells. Cell
Mol Neurobiol. 35:679–687. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chae DK, Park J, Cho M, Ban E, Jang M, Yoo
YS, Kim EE, Baik JH and Song EJ: MiR-195 and miR-497 suppress
tumorigenesis in lung cancer by inhibiting SMURF2-induced TGF-β
receptor I ubiquitination. Mol Oncol. 13:2663–2678. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shen J and Li M: MicroRNA-744 inhibits
cellular proliferation and invasion of colorectal cancer by
directly targeting oncogene notch1. Oncol Res. 26:1401–1409. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen XF and Liu Y: MicroRNA-744 inhibited
cervical cancer growth and progression through apoptosis induction
by regulating Bcl-2. Biomed Pharmacother. 81:379–387. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang J, Cai H, Dai Z and Wang G:
Down-regulation of lncRNA XIST inhibits cell proliferation via
regulating miR-744/RING1 axis in non-small cell lung cancer. Clin
Sci (Lond). 133:1567–1579. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guo Q, Zhang Q, Lu L and Xu Y: Long
noncoding RNA RUSC1-AS1 promotes tumorigenesis in cervical cancer
by acting as a competing endogenous RNA of microRNA-744 and
consequently increasing Bcl-2 expression. Cell Cycle. 19:1222–1235.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Miyamae M, Komatsu S, Ichikawa D,
Kawaguchi T, Hirajima S, Okajima W, Ohashi T, Imamura T, Konishi H
and Shiozaki A: Plasma microRNA profiles: Identification of miR-744
as a novel diagnostic and prognostic biomarker in pancreatic
cancer. Br J Cancer. 113:1467–1476. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kleemann M, Schneider H, Unger K, Sander
P, Schneider EM, Fischer-Posovszky P, Handrick R and Otte K:
MiR-744-5p inducing cell death by directly targeting HNRNPC and
NFIX in ovarian cancer cells. Sci Rep. 8:90202018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen S, Shi F, Zhang W, Zhou Y and Huang
J: miR-744-5p inhibits non-small cell lung cancer proliferation and
invasion by directly targeting PAX2. Technol Cancer Res Treat.
18:15330338198769132019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hübner M, Hinske CL, Effinger D, Wu T,
Thon N, Kreth FW and Kreth S: Intronic miR-744 inhibits
glioblastoma migration by functionally antagonizing its host gene
MAP2K4. Cancers (Basel). 25:4002018. View Article : Google Scholar
|
|
17
|
Deng Y, Li Y, Fang Q, Luo H and Zhu G:
microRNA-744 is downregulated in glioblastoma and inhibits the
aggressive behaviors by directly targeting NOB1. Am J Cancer Res.
8:2238–2253. 2018.PubMed/NCBI
|
|
18
|
Li Y, Gan S, Ren L, Yuan L, Liu J, Wang W,
Wang X, Zhang Y, Jiang J, Zhang F and Qi X: Multifaceted regulation
and functions of replication factor C family in human cancers. Am J
Cancer Res. 8:1343–1355. 2018.PubMed/NCBI
|
|
19
|
Xiong S, Wang Q, Zheng L, Gao F and Li J:
Identification of candidate molecular markers of nasopharyngeal
carcinoma by tissue microarray and in situ hybridization. Med
Oncol. 28 (Suppl 1):S341–S348. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu J, Wang G, Gong W, Guo S, Li D and Zhan
Q: The noncoding function of NELFA mRNA promotes the development of
oesophageal squamous cell carcinoma by regulating the Rad17-RFC2-5
complex. Mol Oncol. 14:611–624. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ho KH, Kuo TC, Lee YT, Chen PH, Shih CM,
Cheng CH, Liu AJ, Lee CC and Chen KC: Xanthohumol regulates
miR-4749-5p-inhibited RFC2 signaling in enhancing temozolomide
cytotoxicity to glioblastoma. Life Sci. 254:1178072020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu T, Shen H, Li J, Yang P, Gu Q and Fu Z:
RFC2, a direct target of miR-744, modulates the cell cycle and
promotes the proliferation of CRC cells. J Cell Physiol.
235:8319–8333. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kato T, Natsume A, Toda H, Iwamizu H,
Sugita T, Hachisu R, Watanabe R, Yuki K, Motomura K, Bankiewicz K
and Wakabayashi T: Efficient delivery of liposome-mediated
MGMT-siRNA reinforces the cytotoxity of temozolomide in
GBM-initiating cells. Gene Ther. 17:1363–1371. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Omuro A and DeAngelis LM: Glioblastoma and
other malignant gliomas: A clinical review. Jama. 310:1842–1850.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gilbert MR, Wang M, Aldape KD, Stupp R,
Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT,
et al: Dose-dense temozolomide for newly diagnosed glioblastoma: A
randomized phase III clinical trial. J Clin Oncol. 31:4085–4091.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cloughesy TF, Cavenee WK and Mischel PS:
Glioblastoma: From molecular pathology to targeted treatment. Ann
Rev Pathol. 9:1–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Johnson DR and O'Neill BP: Glioblastoma
survival in the United States before and during the temozolomide
era. J Neurooncol. 107:359–364. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Luo JW, Wang X, Yang Y and Mao Q: Role of
micro-RNA (miRNA) in pathogenesis of glioblastoma. Eur Rev Med
Pharmacol Sci. 19:1630–1639. 2015.PubMed/NCBI
|
|
30
|
Saadatpour L, Fadaee E, Fadaei S, Mansour
RN, Mohammadi M, Mousavi SM, Goodarzi M, Verdi J and Mirzaei H:
Glioblastoma: Exosome and microRNA as novel diagnosis biomarkers.
Cancer Gene Ther. 23:415–418. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cui JQ, Shi YF and Zhou HJ: Expression of
RFC2 and PCNA in different gestational trophoblastic diseases. Ai
Zheng. 23:196–200. 2004.(In Chinese). PubMed/NCBI
|
|
32
|
Olbrich K, Costard L, Möser CV, Syhr KMJ,
King-Himmelreich TS, Wolters MC, Schmidtko A, Geisslinger G and
Niederberger E: Cleavage of SNAP-25 ameliorates cancer pain in a
mouse model of melanoma. Eur J Pain. 21:101–111. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mu Y, Yan X, Li D, Zhao D, Wang L, Wang X,
Gao D, Yang J, Zhang H, Li Y, et al: NUPR1 maintains autolysosomal
efflux by activating SNAP25 transcription in cancer cells.
Autophagy. 14:654–670. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Antonucci F, Corradini I, Morini R,
Fossati G, Menna E, Pozzi D, Pacioni S, Verderio C, Bacci A and
Matteoli M: Reduced SNAP-25 alters short-term plasticity at
developing glutamatergic synapses. EMBO Rep. 14:645–651. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fulda S, Wick W, Weller M and Debatin KM:
Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced
apoptosis and induce regression of malignant glioma in vivo. Nat
Med. 8:808–815. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shiraishi S, Tada K, Nakamura H, Makino K,
Kochi M, Saya H, Kuratsu Ji and Ushio Y: Influence of p53 mutations
on prognosis of patients with glioblastoma. Cancer. 95:249–257.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu T and Dai Y: Tumor microenvironment and
therapeutic response. Cancer Lett. 387:61–68. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
She X, Yu Z, Cui Y, Lei Q, Wang Z, Xu G,
Xiang J, Wu M and Li G: miR-128 and miR-149 enhance the
chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal
remodeling in glioblastoma. Oncol Rep. 32:957–964. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xu P, Yang J, Liu J, Yang X, Liao J, Yuan
F, Xu Y, Liu B and Chen Q: Identification of glioblastoma gene
prognosis modules based on weighted gene co-expression network
analysis. BMC Med Genomics. 11:962018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xiang Y, Zhang CQ and Huang K: Predicting
glioblastoma prognosis networks using weighted gene co-expression
network analysis on TCGA data. BMC Bioinformatics. 13 (Suppl
2):S122012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kong Y, Feng ZC, Zhang YL, Liu XF, Ma Y,
Zhao ZM, Huang B, Chen AJ, Zhang D, Thorsen F, et al:
Identification of immune-related genes contributing to the
development of glioblastoma using weighted gene co-expression
network analysis. Front Immunol. 11:12812020. View Article : Google Scholar : PubMed/NCBI
|
